Skip to main content

Neil Canavan

Medical Writer
Medical Writer
Authored Items
Rehospitalization Is Driving Costs in Pulmonary Arterial Hypertension
Neil Canavan
November/December 2013, Vol 6, No 9 in Practice Management, Pulmonary
First Cost Analysis of Long-Term Management of CML
Neil Canavan, Neil Canavan
February 2012 Vol 5, No 1, Special Issue
Bosutinib Shows Superior Results in CML
Neil Canavan, Neil Canavan
February 2012 Vol 5, No 1, Special Issue in Leukemia, Oncology
Ready-Made Platelets? A Boon for Patients If It Works
Neil Canavan, Neil Canavan
February 2012 Vol 5, No 1, Special Issue in Conference Highlights ASH
Cost of Treating Myeloproliferative Neoplasms Is Significant
Neil Canavan, Neil Canavan
February 2012 Vol 5, No 1, Special Issue
Investigational Blinatumomab Puts BiTE on Acute Lymphoblastic Leukemia
Neil Canavan
February 2012 Vol 5, No 1, Special Issue in Leukemia, Oncology
Hematologists Are Told to Get Ready for ACOs
Neil Canavan, Neil Canavan
February 2012 Vol 5, No 1, Special Issue
Chronic Myeloid Leukemia: Are We Close to Finding a Cure?
Neil Canavan, Neil Canavan
February 2012 Vol 5, No 1, Special Issue
Favorable Data for Ruxolitinib and for a New JAK Inhibitor in Myelofibrosis
Neil Canavan, Neil Canavan
February 2012 Vol 5, No 1, Special Issue in Conference Highlights ASH
DVT Prophylaxis: First Comparison of Catheter- Directed Thrombolysis versus Standard Care
Neil Canavan, Neil Canavan
February 2012 Vol 5, No 1, Special Issue in Conference Highlights ASH
Ponatinib Overcomes Hard-to-Treat T315I Mutation in Patients with CML/ALL
Neil Canavan, Neil Canavan
February 2012 Vol 5, No 1, Special Issue in Leukemia, Oncology
Last modified: December 19, 2013